The Clinical Aspects and Prognostic Factors Concerning Survival in Patients With Recurrent Cervical Cancer After Radical Hysterectomy and Adjuvant Chemoradiotherapy

被引:1
|
作者
Zhu, Hui-Ting [1 ]
Yan, Wen-Juan [2 ]
Gao, Yu-Hua [1 ]
机构
[1] China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Dept Gynecol, Shenyang, Peoples R China
[2] Peoples Liberat Army PLA, Gen Hosp Eastern Theater Command, Dept Gen Surg, Nanjing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
关键词
recurrent cervical cancer; prognostic factors; survival; radical surgery; radiotherapy; chemotherapy; PELVIC RADIATION-THERAPY; CARCINOMA; STAGE; LYMPHADENECTOMY; OUTCOMES; SURGERY;
D O I
10.3389/fonc.2021.782403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo investigate the recurrence patterns and prognostic factors of patients with recurrent cervical cancer after radical hysterectomy with node dissection (RHND) followed by adjuvant radiotherapy (RT)/concurrent chemoradiotherapy (CCRT). MethodsThe medical records of 153 patients with pre-operative International Federation of Gynecology and Obstetrics stage IB-IIA cervical cancer, who were treated with RHND followed by adjuvant RT/CCRT at the Liaoning Cancer Hospital between January 1, 2012 and May 31, 2018, were retrospectively analyzed. ResultsThe median disease progression-free survival time was 16 months, and 75.2% (115/153) of patients had a relapse within two years. The survival of patients with multi-site relapse was significantly lower in comparison to those with relapse in a single site (p < 0.001). The survival rate of patients with distant metastasis (DM) and combined recurrence (DM with localregional recurrence [LR]) was significantly lower than that of patients with only LR (p = 0.006, p < 0.001). Furthermore, the survival rate of patients with combined recurrence was significantly lower than that of patients with only DM (p = 0.046). Multivariate analysis showed that resection margin involvement, para-aortic and common iliac lymph node metastasis, DM, no treatment after disease relapse, and early disease relapse were independent prognostic factors associated with poor survival. ConclusionMost of the cervical cancer patients who received initial RHND followed by adjuvant RT/CCRT had a relapse within two years. Resection margin involvement, para-aortic and common iliac lymph node metastasis, DM, no treatment after recurrence, and early disease relapse were found to be prognostic factors in patients with recurrent cervical cancer after RHND followed by adjuvant RT/CCRT.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy
    Li, Dan
    Xu, Xiaoxian
    Yan, Dingding
    Yuan, Shuhui
    Ni, Juan
    Lou, Hanmei
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [22] Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy
    Hosaka, Masayoshi
    Watari, Hidemichi
    Kato, Tatsuya
    Odagiri, Tetsuji
    Konno, Yousuke
    Endo, Daisuke
    Mitamura, Takashi
    Kikawa, Satomi
    Suzuki, Yoshihiro
    Sakuragi, Noriaki
    JOURNAL OF SURGICAL ONCOLOGY, 2012, 105 (06) : 612 - 616
  • [23] Comparison of Survival Outcomes after Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Cervical Cancer
    Hwang, Jong Ha
    Kim, Bo Wook
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2021, 28 (05) : 971 - +
  • [24] Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study)
    Nakamura, Kazuto
    Kitahara, Yoshikazu
    Satoh, Toyomi
    Takei, Yuji
    Takano, Masashi
    Nagao, Shoji
    Sekiguchi, Isao
    Suzuki, Mitsuaki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [25] IS ADJUVANT CHEMORADIOTHERAPY OVERTREATMENT IN CERVICAL CANCER PATIENTS WITH INTERMEDIATE RISK FACTORS?
    Ryu, Sang-Young
    Park, Sang-Il
    Nam, Byung-Ho
    Cho, Chul-Koo
    Kim, Kidong
    Kim, Beob-Jong
    Kim, Moon-Hong
    Choi, Seok-Cheol
    Lee, Eui-Don
    Lee, Kyoung-Hee
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (03): : 794 - 799
  • [26] Survival and Prognostic Factors Comparing Stage IB 1 versus Stage IB 2 Cervical Cancer Treated with Primary Radical Hysterectomy
    Srisomboon, Jatupol
    Kietpeerakool, Chumnan
    Suprasert, Prapaporn
    Manopanya, Manatsawee
    Siriaree, Sitthicha
    Charoenkwan, Kittipat
    Cheewakriangkrai, Chalong
    Sae-Teng, Charuwan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (07) : 1753 - 1756
  • [27] Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
    Faivre, Jean-Christophe
    Jung, Paul
    Salleron, Julia
    Baumard, Florian
    Courrech, Florent
    Marchal, Frederic
    Peiffert, Didier
    Renard, Sophie
    Charra-Brunaud, Claire
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2023, 15 (01) : 27 - 36
  • [28] Prediction of Postoperative Pathologic Risk Factors in Cervical Cancer Patients Treated with Radical Hysterectomy by Machine Learning
    Ou, Zhengjie
    Mao, Wei
    Tan, Lihua
    Yang, Yanli
    Liu, Shuanghuan
    Zhang, Yanan
    Li, Bin
    Zhao, Dan
    CURRENT ONCOLOGY, 2022, 29 (12) : 9613 - 9629
  • [29] Salvage radiotherapy strategy and its prognostic significance for patients with locoregional recurrent cervical cancer after radical hysterectomy: a multicenter retrospective 10-year analysis
    Shan, Minjie
    Deng, Yuping
    Zou, Wen
    Fan, Shasha
    Li, Yanlong
    Liu, Xianling
    Wang, Jingjing
    BMC CANCER, 2023, 23 (01)
  • [30] Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy
    Kim, Sang-Won
    Chun, Mison
    Ryu, Hee-Sug
    Chang, Suk-Joon
    Kong, Tae Wook
    Oh, Young-Taek
    Kang, Seung Hee
    BMC CANCER, 2017, 17